Ovalbumin and Poly(i:c) Encapsulated Dendritic Cell-Targeted Nanoparticles for Immune Activation in the Small...

Area of Science:

• Immunology
• Nanotechnology
• Cancer Research

Background:

• Melanoma development poses a significant challenge, necessitating novel therapeutic strategies.
• Targeting the immune system, particularly dendritic cells, is crucial for effective cancer prevention.
• Oral delivery systems offer potential advantages for drug administration and immune activation.

Purpose of the Study:

• To develop and evaluate antigen and adjuvant-loaded nanoparticles for targeted immune activation.
• To investigate the efficacy of oral nanoparticle delivery in inhibiting melanoma development.
• To assess the impact of nanoparticles on dendritic cell maturation and immune responses.

Main Methods:

• Chondroitin sulfate-coated nanoparticles (OPGMN) were engineered with glycocholic acid and mannose for cationic liposomes.
• Ovalbumin (antigen) and polyinosine-polycytidylic acid (adjuvant) were encapsulated within OPGMN.
• OPGMN was orally administered to a B16F10 melanoma mouse model.
• Immune cell populations (dendritic cells, T cells, NK cells, regulatory T cells) and cytokine profiles were analyzed.

Main Results:

• Oral OPGMN delivery successfully targeted dendritic cells in the small intestinal lymphatic system and lymph nodes.
• OPGMN induced enhanced dendritic cell maturation and robust T helper type 1 and type 2 immune responses.
• Repeated oral administration increased populations of cytotoxic T cells, memory T cells, and natural killer cells.
• OPGMN completely prevented melanoma development by reducing regulatory T cells.

Conclusions:

• Oral nanoparticle-based immunotherapy is a promising strategy for melanoma prevention.
• This approach effectively modulates immune responses and inhibits tumor development.
• The strategy holds potential for preventing tumor recurrence post-treatment.